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Immunologic Complexity Minireview
in Neurons
mRNA expression. Although many immunoglobulin su-
perfamily members are expressed in neurons, they do
not have the complexity evident in immune cell recep-
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New York, New York 10021 tors. Specific assays for MHC expression in neurons in
vivo have generally been negative (Lampson, 1995).
More recent studies analyzing RNA transcripts in disso-
The nervous system and the immune system face a ciated neurons in tissue culture have suggested that
common challenge: how to encode for very complex neuronal MHC gene expression may be inducible, by
functions using a genome of limited size. A mere 105 the addition of cytokines or by electrical silencing with
primary RNA transcripts apparently encode for the com- tetrodotoxin (TTX) (Neumann et al., 1995, 1997), but the
plexity of the mammalian brain, which has an estimated functional significance of the MHC expression was still
1010 neurons. Moreover, each neuron must make thou- subject to debate. The conventional wisdom that im-
sands of specific synaptic connections with other neu- mune recognition molecules are not present in the CNS
rons. In the immune system, where T cells and B cells has now been challenged by the study of Shatz and
have nearly unlimited abilities to recognize foreign anti- colleagues (Corriveau et al., 1998), whose data suggest
gens, the problem of complexity has been solved in the widespread use of a network of MHC I receptor±
several ways. Combinatorial diversity through germline ligand systems in electrically active neurons at times
rearrangement, somatic mutation, and differential RNA when they are undergoing remodeling and synaptic plas-
splicing generates receptors that harbor variable re-
ticity. Shatz and colleagues began by searching for
gions of immense complexity and specificity. In neu-
genes regulated by spontaneous neural activity in the
rons, although complex patterns of alternative splicing
developing visual system. Fetal cats were surgically im-
of some pre-mRNAs and RNA editing (a special example
planted with osmotic minipumps that infused TTX intoof somatic mutation at the RNA level) contribute to diver-
the lateral ventricle, a method previously determined tosity, immune system±like mechanisms that generate
block electrical activity in the lateral geniculate nucleusfunctional complexity have not been found. The recent
(LGN). Surprisingly, an initial dot blot comparison offindings by Corriveau et al. (1998) that neurons regulate
RNAs isolated from control and TTX-treated LGNs re-the expression of components of an immune recognition
vealed that none of 32 genes known to be regulated bysystem under physiologically relevant conditions raise
neuronal activity in the adult hippocampus are regulatedthe question of whether neurons use this system in a
in the LGN by TTX treatment. This observation suggestsclassical way to generate diversity, or whether they uti-
there may be differences in the ways in which genelize it in a still undiscovered manner.
expression is altered by hippocampal activity and ac-Molecular Basis of Immune Cell Diversity
tivity present during embryonic eye-specific layer for-Diversity in the immune system is used to establish an
mation.essentially unlimited array of complex receptor±ligand
In an effort to identify novel genes whose expressioninteractions. In B cells, the interactions occur between
may be regulated by activity during development, Corri-the variable region of antibodies and different antigens.
veau et al. (1998) performed a differential display onIn T cells, the interactions occur between the variable
RNA expressed in control and TTX-treated LGNs. A sin-region of T cell receptors (TCRs) and cell surface pro-
teins encoded by a set of genes termed the major histo- gle mRNA was markedly repressed in the TTX-treated
compatibility complex (MHC). MHC molecules play an LGN. This mRNA was derived from a gene encoding a
essential role in immunologic diversity by presenting on class I MHC molecule. Rigorous control experiments
the cell surface peptides that are derived from intracellu- bolster the significance of this observation. The authors
lar proteolysis; these peptides can then in turn be recog- found class I MHC expression in neurons using both in
nized by TCRs. There are two different types of MHC situ hybridization and sensitive immunohistochemical
molecules: class I, which present peptides to cytotoxic techniques. Of importance, they extended these results
T cells (CD81 cells), and class II, which present peptides by documenting neuronal expression of several other
to helper T cells (CD41 cells). MHC I molecules function components of the MHC I signaling apparatusÐb2 mi-
classically as heterotrimers consisting of a heavy chain, croglobulin and CD3z, one of the key proteins associ-
which presents peptide, and an invariant light chain, ated with functional TCRs.
termed b2-microglobulin. TCRs function as heterodi- Corriveau et al. (1998) also demonstrated expression
mers that associate with a number of integral membrane of MHC I genes in several biologically relevant contexts.
signaling proteins. Expression of different subclasses of MHC I genes was
MHC I in Neurons downregulated in the LGN following TTX blockade of
Many groups have assessed whether the molecules neuronal activity, and MHC I mRNA expression was
used to generate immunologic diversity are used in neu- upregulated in the hippocampus and neocortex follow-
rons. Such studies originally used immunohistochemical
ing kainic acid±induced seizures. These observations sug-
methods and more recently have included analysis of
gest that MHC I proteins may provide activity-depen-




MHC I and CD3 Signaling Pathways in Neurons immune cells in b2 microglobulin null mice (Zijlstra et
al., 1990). Since neuronal MHC I expression can in someThe detection of b2 microglobulin in conjunction with
instances be uncoupled from b2 microglobulin expres-MHC I in neurons is significant. b2 microglobulin is be-
sion, MHC I could operate in neurons in a nonclassicallieved to play a critical role in allowing intact MHC I
fashion, independently from b2 microglobulin. However,molecules to assemble on the cell surface. Neurons in
while MHC I molecules might function differently in neu-vitro can be induced to make MHC I in the absence
rons and immune cells, a detailed analysis of the expres-of b2 microglobulin expression (Neumann et al., 1995,
sion and function of individual MHC I signaling compo-1997), and this observation has supported the notion
nents remains to be worked out. In this respect, carefulthat MHC I may not be functional in neurons. While the
neurologic evaluation of mice harboring null mutationsShatz paper concurs with the finding that MHC I and b2
in MHC I signaling pathways is likely to be helpful. Formicroglobulin can be independently regulated by neu-
example, b2 microglobulin null mice, which lack CD81ronal activity (MHC I but not b2 micoglobulin is increased
T cells (Zijlstra et al., 1990), appear normal but have notin the hippocampus following kainate acid±induced sei-
been studied neurologically.zures), their documentation of b2 microglobulin expres-
MHC I and Synaptic Plasticity: Lessonssion in neurons is consistent with the presence of a
from the Immune Systemfunctioning MHC I signaling system.
Although not all components of the MHC I signalingDetection of CD3z, while only one component of com-
system have yet been examined in neurons, those thatplete TCRs, strongly suggests the possibility that func-
have been identified seem well suited for providing spe-tional receptors might exist in neurons. One of the major
cific signaling pathways. The clearest example from thefunctions of CD3 proteins is to facilitate TCR expression
Shatz paper is in the visual system. Presynaptic LGNon the cell surface; conversely, cells do not stably ex-
neurons express the TCR component CD3z, and post-press CD3 on their surface unless they also express
synaptic layer IV neurons in the visual cortex expressTCR (Ashwell and Klausner, 1990). The nearly obligate
MHC I in dendritic processes. These observations ledcoupling of CD3z with a second receptor molecule de-
Shatz and colleagues to propose two related neuronalrives from the unusual placement of a positively charged
activities for MHC I molecules in the brain. First, a cellularamino acid within the transmembrane domain of CD3z,
recognition function was suggested, in which dendriticwhich is stablized only by an intermolecular reaction
MHC I molecules might act as a ªsynaptic glueº to stabi-with a negatively charged amino acid within the trans-
lize appropriate and active synapses. This suggestion
membrane domain of TCR. Thus, the presence of CD3z
is consistent with the observed induction of MHC I by
in neurons predicts the presence of a TCR (or a neuronal
synaptic activity, although detailed cell biology will be
TCR variant; see below). required to demonstrate that MHC I signaling compo-
CD3z is also significant in that it is largely responsible nents are in appropriate regions of axons and dendrites.
for coupling TCR occupancy (by MHC I) to several intra- Second, consideration is given to retrograde triggering
cellular signaling pathways, all of which are known to of presynaptic receptors containing CD3z by postsynap-
be important in neurons. These include independent tic MHC I molecules, whereby CD3z (or other receptor
actions to (1) activate receptor tyrosine kinases, allowing components) may transduce neuronal signals regulating
activation of the src kinases fyn and lck; (2) activate such activities as neurite outgrowth or hippocampal
the guanine nucleotide binding protein p21ras; and (3) long-term potentiation (LTP).
activate phospholipase Cg1, which allows TCR to regu- One of the fascinating issues in considering neuronal
late intracellular calcium levels and protein kinase C MHC I signaling is the enormous degree of complexity
(Cantrell, 1996). To illustrate with only one example, fyn it suggests. In immune cells, this signaling occurs be-
is present in nerve growth cones and axonal tracts, and tween a unique TCR expressed in an individual T cell
fyn null mice show many behavioral defects, several of clone and one of the thousands of different MHC±pep-
which suggest that fyn signaling is important in synaptic tide complexes it sorts through on a single target cell.
plasticity. Clearly, CD3z-mediated signaling from MHC Each MHC I molecule presents a unique peptide loaded
I±TCR complexes could regulate crucial functions in onto it by protein pumps present in the endoplasmic
neurons. reticulum, such that the collection of MHC I molecules
It is worthwhile considering that MHC I signaling may on the surface of a cell are a full representation of the
operate in novel ways in neurons, and that all compo- proteins expressed within that cell. A specific interaction
nents of typical immune signaling pathways might not of this MHC I peptide complex (in the appropriate set-
be coordinately used in the brain. Atypical TCRs, or ting; see below) with TCR will suffice to activate a T cell
other equivalent binding proteins, might exist in neu- clone. In neurons, by analogy, an axon bearing a single
rons. For example, three distinct families of receptors TCR ªcloneº could ªsearchº many target cells, assessing
that recognize MHC I molecules have been found in their complete phenotype via peptides presented by
natural killer cells (reviewed by Lanier, 1998). Moreover, MHC I molecules (Figure 1). A specific target cell need
CD3 proteins, including CD3z, associate not only with only express a unique peptide that is recognized by the
the classical heterodimeric (ab) TCR but also with atypi- axonal TCR, to allow a unique signal to be transduced
cal receptors such as the gd TCR. between presynaptic and postsynaptic neurons. This
Unusual conformations of MHC I molecules may also suggests that MHC I molecules could provide a system
be present in neurons. Some cell surface MHC I expres- with potential signaling specificity parallel to that pres-
sion in immune cells is normally independent of b2 mi- ent in systems where axon guidance is mediated by
croglobulin expression (Allen et al., 1986), and small dedicated receptor±ligand systems, but with vastly
greater complexity.amounts of MHC I can be detected on the surface of
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qualitative change in a presynaptic cell. Moreover, the
ªoffº signal in immune cells can include triggering of
apoptotic cell death, mediated by pathways (e.g., bcl-
xL; Lenschow et al., 1996) of established importance
in both developing and postnatal neurons (Merry and
Korsmeyer, 1997; Parsadanian et al., 1998). In neurons,
as in T cells, the positive triggering of two signals could
lead to long-term changes in presynaptic cells, allowing
conversion of negative (repulsive or apoptotic) signals
into positive (attractive) ones. Such qualitative changes
are of interest in considering problems of axon guidance
as well as problems of long-term changes in individual
synapses.
MHC I signaling may also be locally regulated in the
brain in ways predicted by the immune system. TCR
signaling is critically regulated by cytokines, and cyto-
kine expression is believed to be locally regulated in
the nervous system. For example, one of the principle
actions of coincident stimulation by signals 1 and 2 is
to allow T cell autocrine stimulation by IL-2, and IL-2
in turn has been proposed to have critical actions in
regulating neuronal activity and survival. In addition,
after viral infection of mouse brain, cytokine induction
by cells other than lymphocytes is able to induce MHC
I expression in the CNS. Taken together, these consider-
ations underscore the importance of examining neurons
for expression of cytokine and costimulatory genes in
Figure 1. Receptor±MHC I Signaling Pathways parallel with the study of MHC I signaling pathways.
T cell receptors present in a single cell have absolute specificity for MHC I and Immune Privilege
MHC molecules bearing one specific peptide. T cells (A) scan targets The finding of MHC I expression in neurons also has
for MHC bearing that peptide. Engagement of a TCR with an appro-
significance regarding the brain as an immune-privi-priate MHC I±peptide complex (signal 1) will suppress the T cell
leged site. Immune privilege was originally defined asimmune response. Such T cells are tolerized (negatively selected),
the ability of certain tissues to accept foreign tissueand subsequent encounter with signal 1 may lead to T cell deletion
by apoptosis (activation-induced cell death). Such inhibitory signals grafts that would otherwise be rejected; this concept
may involve additional receptor ligand interactions that are not illus- has been extended to the brain, the anterior chamber
trated, such as interaction of B7 ligands with the CTLA4 receptor of the eye, and the testis. Immune privilege in the brain
(Greenfield et al., 1998). Activation of T cells requires both signal 1
is believed to underlie the difficulty immune cells haveand interactions between costimulator molecules (signal 2) such as
in destroying neurons, particularly by T cell mechanismsthe interaction of B7 ligands with the CD28 receptor molecule on T
that would utilize MHC I molecules, such as the destruc-cells. This costimulation leads to signals (such as the induction
of IL-2 expression) that activate T cells in an autocrine fashion. tion of virally infected cells. Thus, the absence of neu-
Subsequent T cell encounters with signal 1 alone will now trigger ronal MHC I expression has been invoked as a mecha-
positive signals. In neurons (B), identification of T cell receptor sig- nism to explain neuronal immune privilege (Lampson,
naling components (CD3z) and MHC I suggests similar complexities
1987; Joly et al., 1991).may mediate interneuronal sorting and signaling cues in the brain.
If we accept MHC I utilization in neurons in vivo, im-
mune privilege in neurons most likely involves other as-
Another layer of complexity in neuronal signaling is sug- pects of immune surveillance. Some experimental evi-
gested by considering that immune cells utilize MHC I dence suggests that MHC I expression is not the sole
signaling in a binary fashion to activate or suppress cellu- determinant of neuronal immune privilege. For example,
lar function (Figure 1). Naive T cells initially encountering even when transgenic mice expressing MHC I from a
MHC I signals (signal 1) are actively suppressed, whereas neuron-specific enolase promoter are infected with a
such cells encountering MHC I signals together with neurotropic virus, they still fail to show evidence of neu-
a specific second signaling system (costimulators and ronal cytotoxicity (Rall et al., 1995).
adhesion molecules, signal 2) are activated (Lenschow The determinants of a neuron's ability to evade im-
et al., 1996; Greenfield et al., 1998). Interestingly, after mune recognition thus remain unknown. Some mecha-
specialized cells presenting both signals 1 and 2 activate nisms to consider are the presence or activity of den-
T cells, T cells subsequently respond positively to pep- dritic cells in the brain, neuronal expression of cell death
tide±MHC I complexes even in the absence of signal 2. genes (e.g., fas ligand) that can permit cells to evade
This mechanism amplifies the signal-to-noise ratio of immune recognition (Ferguson and Griffith, 1997), neu-
the system, and it has implications for neuronal signal- ronal expression of genes that suppress apoptotic death
ing. With respect to axon±dendrite interactions, these (Merry and Korsmeyer, 1997), or the expression of cyto-
observations suggest that the default state for this path- kines, which may influence any of these variables or
way might be actively kept ªoff,º until a special switch neuronal MHC I gene expression itself (Neumann et al.,
1995, 1997).(peptide±MHC I plus an additional ªsignal 2º) triggers a
Neuron
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MHC I and Neurologic Disease Conclusions
The study of MHC I expression in neurons has beenSome autoimmune neurologic diseases reflect the im-
mune-privileged status of neuronal antigens, most nota- plagued by large numbers of conflicting reports. Al-
though more sensitive studies using PCR-based analy-bly the paraneoplastic neurologic disorders (PNDs; re-
viewed by Darnell, 1996). PNDs are believed to develop sis of gene expression have recently demonstrated MHC
I expression in cultured neurons, the current work ofwhen tumor cells express antigens that are normally
made only in neurons (termed onconeural antigens), Shatz and colleagues demonstrating MHC I expression
in neurons in vivo allows consideration of new and unex-leading to an immune response that initially targets tu-
mor cells but eventually kills neurons. Recently, cyto- pected conclusions regarding the relationship between
MHC I expression and neuronal activity. Moreover, thetoxic T lymphocytes that specifically kill target cells ex-
pressing onconeural antigens have been found in PND study provides new direction to the search for molecular
mechanisms underlying complexity in the brain, by sug-patients (Albert et al., 1998), suggesting that immune
recognition of MHC I molecules harboring onconeural gesting the need to reevaluate whether the mechanisms
by which T cell clones generate diversity are also utilizedpeptides could be important in both tumor immunity
and neuronal autoimmunity in these disorders. However, by individual neurons.
there is a dissociation between the development of tu-
Selected Readingmor immunity and neuronal autoimmunity in PND, sug-
gesting a difference between the way in which the im-
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ing neuronal immune privilege underlie this divergence. Cantrell, D. (1996). Annu. Rev. Immunol. 14, 259±274.
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Purkinje neurons, preferentially express high levels of Joly, E., Mucke, L., and Oldstone, M.B.A. (1991). Science 253, 1283±
1285.MHC I (Corriveau et al., 1998) suggests that such neu-
rons may be particularly susceptible to autoimmune at- Lampson, L.A. (1987). Trends Neurosci. 10, 211±216.
tack. This finding is consistent with the observation that Lampson, L.A. (1995). Microsc. Res. Tech. 32, 267±285.
some PNDs specifically affect the limbic system or cere- Lanier, L.L. (1998). Annu. Rev. Immunol. 16, 359±393.
bellum, even though the target antigens are expressed Lenschow, D.J., Walunas, T.L., and Bluestone, J.A. (1996). Annu.
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245±267.The observation that MHC I expression is induced in
vivo by neuronal activity, including kainic acid±induced Neumann, H., Cavalie, A., Jenne, D.E., and Wekerle, H. (1995). Sci-
ence 269, 549±552.seizures (Corriveau et al., 1998), suggests the possibility
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of damage such as excitotoxicity, contribute to long-
term sequelae of epilepsy such as mesial temporal scle-
rosis. Moreover, one epileptic condition, Rasmussen's
encephalitis, has been proposed to have an immuno-
logic basis associated with the development of antibod-
ies to the glutamate receptor GluR3. This disorder has
been difficult to reproduce in animals, and GluR3 anti-
bodies do not appear to induce excitotoxic neuronal
damage (He et al., 1998). Taken together, these observa-
tions suggest that repeated seizures in Rasmussen's
encephalitis may lead to the induction of class I MHC
molecules and thereby to the secondary induction of
GluR3 antibodies.
